Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Starting soon · Not applicable

Conditions studied: HER2+ Metastatic Breast Cancer (MBC)

In brief

The goal of this study is to test a novel nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer (mBC) receiving tucatinib, trastuzumab, and capecitabine. The program will focus on enhancing understanding of the treatment regimen, managing symptoms and adherence, and improving coping and self-management skills. If successful, the program could be integrated into clinical care to better support mBC patients. The main question the study aims to answer is: is the patient navigation program feasible and acceptable for mBC patients? Participants will receive patient navigation sessions over about 6 weeks. Participants will also complete study assessments via electronic survey at baseline and at about 3 and 6 weeks after enrollment, with the last assessment occurring after completion of the patient navigation program sessions. Participants will also complete a post-program exit interview.

Key facts

Study ID

NCT06983691

Run by

Duke University

People needed

26

Starts

2026-08-01

Expected to finish

2027-03-01

Last updated by the study team

2026-08-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• female (sex assigned at birth);
• ≥18 years of age at enrollment;
• diagnosed with HER2+ metastatic breast cancer (mBC);
• receiving treatment with tucatinib combined with capecitabine and trastuzumab;
• able to speak and read English

You may not qualify if…

• visual or hearing impairment;
• severe cognitive impairment;
• severe mental illness interfering with ability to participate

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.